New biologic shot aims to tame painful skin disease
NCT ID NCT06361836
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a single dose of a new biologic drug, SBT777101, in 24 adults with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful abscesses and tunnels). The main goal is to check safety and side effects at increasing dose levels. Researchers will also look at how the drug moves through the body and any signs it might reduce disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SBT777101 (a biologic drug given as a single dose)
- What this could lead to
- If it works, this could point toward a new treatment option for hidradenitis suppurativa that reduces painful skin abscesses and inflammation.
- What could go wrong
- This is a very early Phase 1 trial with only 24 people, focused on safety. It is too small and early to know if the drug actually helps symptoms, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Duke University
Durham, North Carolina, 27708, United States
-
SLUCare Academic Pavillion
St Louis, Missouri, 63110, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Head-to-Head: which pill tames hidradenitis suppurativa best?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could early treatment tame a painful skin condition?
- New pill shows promise for controlling painful skin condition in long-term trial
- New shot could ease painful skin condition
- New pill for painful skin disease enters first human tests